Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XB628 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Phase | EXPERIMENTAL | Participants with recurrent advanced or metastatic solid tumors will receive escalating dose levels doses of XB628 as a single agent and in combination with zanzalintinib. |
| Dose Expansion | EXPERIMENTAL | Participants with recurrent advanced or metastatic solid tumors will receive XB628 as a single agent and in combination with zanzalintinib. |
| Name | Type | Description |
|---|---|---|
| XB628 | BIOLOGICAL | Intravenous infusion(s) |
| Zanzalintinib | DRUG | Oral tablet(s) |
Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Minimum life expectancy of ≥ 12 weeks. * Have a recurrent advanced or metastatic solid tumor that is histologically or cytologically confirmed. * Adequate organ and marrow function. * Not amenable to...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
XB628 is an investigational bispecific monoclonal antibody being studied for the treatment of recurrent advanced or metastatic solid tumors, including immune-sensitive tumors. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
XB628 targets PD-L1 and NKG2A, two proteins involved in immune regulation. By binding to both targets, the bispecific antibody is designed to modulate immune responses against tumor cells. This dual targeting is being evaluated in the context of solid tumor malignancies.
XB628 is being developed by Exelixis, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol EXEL. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational agent in patients with advanced or metastatic solid tumors.
XB628 is in Phase 1 clinical development. The drug is being studied in an early-stage trial that is currently recruiting participants. As an investigational agent, XB628 has not yet received regulatory approval and remains under evaluation for safety and dosing.
XB628 is being evaluated in a Phase 1 clinical trial registered as NCT06952010. This study assesses XB628 alone and in combination with zanzalintinib in participants with recurrent advanced or metastatic solid tumors. The trial is actively recruiting in the United States and aims to enroll approximately 303 participants.
No, XB628 is not the same as zanzalintinib. XB628 is a bispecific monoclonal antibody targeting PD-L1 and NKG2A, while zanzalintinib is a separate investigational agent. In the ongoing clinical trial, XB628 is being studied both alone and in combination with zanzalintinib to assess their potential therapeutic effects.